Zydus Lifesciences Ltd announced on Friday that the United States Food and Drug Administration (USFDA) has successfully completed an inspection of its Ahmedabad facility without any observations.
The US health regulator inspected the company’s Topical Manufacturing site in Changodar, Ahmedabad, as part of a routine surveillance inspection conducted between February 10 and February 14. The inspection concluded with zero observations, the company stated in a press release.
Meanwhile, Zydus Lifesciences reported strong financial performance in Q3 FY25. The company’s net profit surged 30% year-on-year (YoY) to Rs 1,023 crore for the quarter ending December 31, 2024, compared to Rs 789 crore in the same period last year. This profit growth was primarily driven by a sharp rise in forex gains, which jumped 771.42% YoY to Rs 183 crore from Rs 21 crore a year ago.
The company’s revenue for the December 2024 quarter increased 17% YoY to Rs 5,269 crore. US formulation sales grew 29% YoY to $285 million, surpassing the estimated $270 million, with the US market contributing nearly 47% to Zydus Lifesciences’ total revenue.
Additionally, the company’s EBITDA rose 25.9% YoY to Rs 1,387 crore in Q3 FY25, up from Rs 1,102 crore in the previous year. The EBITDA margin expanded by nearly 200 basis points (bps) to 26.3% from 24.5% in the same period last year.
Sharvil Patel, Managing Director of Zydus Lifesciences, said, “Our robust portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in international markets position us well for future growth.”
At 3:30 pm, the shares of Zydus Lifesciences closed 4.62% lower at Rs 899.30 on NSE.
Navigate Zydus Lifesciences Like a Pro. Ask the Analyst.
Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!
